Alnylam Pharmaceuticals valuation
$156.50Change from previous close: −2.02%Absolute change: −$3.23
Valuation
The P/E ratio is 8.34. The average price target of 27 analysts is $299.96.
Data as of November 15, 2026
Alnylam Pharmaceuticals compared with similar companies
Alnylam Pharmaceuticals's P/E (trailing 12 months): 8.34, −71% against the median of a group of 6 similar companies (29.2).
| Metric | Alnylam Pharmaceuticals | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 8.34 | 29.2 | 18.6 – 55.3 | Low |
| Forward P/E | 15.2 | 15.2 | 11.5 – 19.3 | Middle |
| EV/EBITDA | 20.8 | 13.4 | 10.5 – 19.4 | High |
| Price/book | 6.13 | 8.03 | 4.77 – 14.3 | Middle |
| Price/sales | 4.41 | 8.14 | 4.95 – 15.9 | Low |
| Gross margin | 77.3% | 77.3% | 66.1% – 91.5% | Middle |
| Operating margin | 19.5% | 19.5% | -48.6% – 31.6% | Middle |
| Net margin | 52.8% | 4.4% | -19.9% – 30.2% | High |
| ROE | 138.1% | 7.8% | -8.3% – 88.3% | High |
| Debt/equity | 0.83 | 0.30 | 0.02 – 0.92 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $22.11B
- Enterprise value
- $21.51B
- PEG
- 0.22
- EV/revenue
- 4.29
Profitability and growth
- ROA
- 9.5%
- ROIC
- 17.0%
- Revenue growth (year over year)
- 16.7%
- Earnings growth (year over year)
- 633.5%
Financial health
- Total cash
- $3.59B
- Total debt
- $3B
- Current ratio
- 2.48
- Quick ratio
- 2.27
- Altman Z-Score
- 6.83
- Piotroski F-Score
- 5.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $299.96
- Median price target
- $299.00
- High price target
- $455.00
- Low price target
- $180.00
- Analysts with a price target
- 27
- Consensus
- Buy
- Forward EPS
- $10.83
- EPS estimate, current year
- $22.68
Shares and trading
- Beta
- 0.44
- Average volume
- 2.05M
- Shares outstanding
- 133.94M
- Float
- 133.62M
- Institutional ownership
- 101.6%
- Insider ownership
- 0.5%
- Short interest (% of float)
- 5.4%
- Short ratio (days)
- 2.61
